UPDATE: Credit Suisse Initiates PDL Biopharma at Neutral on Dividend Continuity Questions
Credit Suisse initiated coverage on PDL Biopharma (NASDAQ: PDLI) with a Neutral rating and a $6.50 price target.
Credit Suisse noted, "PDLI is unique among biotech companies, collecting royalties from some of the industry's biggest blockbuster antibodies and paying investors a high dividend, which we believe is fully reflected in its price. PDLI's value is primarily derived from Roche's antibody products, but increasingly it fortunes are tied to Eli Lilly's solanezumab. … PDLI is also leveraged to outperform Roche's products, for example Perjeta and T-DM1. We also expect an update to PDLI's plans to return capital to investors, potentially on its year-end conference call, which could include a special dividend."
PDL Biopharma closed at $7.83 on Monday.
Latest Ratings for PDLI
|May 2013||Piper Jaffray||Initiates Coverage on||Neutral|
|Mar 2013||JP Morgan||Maintains||Neutral|
|Jan 2013||Credit Suisse||Downgrades||Neutral||Underperform|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.